Pancreatic Ductal Adenocarcinoma

Erastin, a ferroptosis inducer, enhanced ferroptosis in CEP55-deficient cells and counteracted the tumor-promoting effects of CEP55 overexpression. In vivo, CEP55 silencing reduced tumor growth and altered ferroptosis markers. Our findings establish CEP55 as a novel driver of PC progression via ferroptosis suppression, supporting its potential as both a prognostic biomarker and a therapeutic target for combination strategies aimed at overcoming PC resistance.

A moderate positive correlation was observed between PD-L1 expression and FDG uptake (R2 = 0.36) and a weaker correlation with FAPI uptake (R2 = 0.19). This Multi-parametric imaging can enhance immunohistochemistry, aiding in patient stratification for immunotherapy and overcoming the limitations of single-site biopsies.

Notably, it identifies key signature patterns that improve early-stage (I/II) PDAC diagnosis and perform well with small sample sizes (n = 50). TabPFN-PanMETAI offers a rapid, accurate, and non-invasive tool for early PDAC detection, with strong potential for clinical application.

P3, N=614, Not yet recruiting, Astellas Pharma Global Development, Inc.

P=N/A, N=56, Recruiting, Shandong Cancer Hospital and Institute

In this study, we hypothesize that SB-216 and Veru-111 (related novel compounds) inhibit cell growth via suppression of oncogenic βIII- and βIVb-tubulin subtypes and mitochondria function via suppression of BRD4, the most active BET protein...Our data demonstrates that SB-216 effectively inhibits PDAC cell growth through inhibiting oncogenic microtubules and mitochondrial function. This novel approach simultaneously targets two hallmarks of cancer and patient demise.

Preclinical studies demonstrate that ATR inhibition disrupts replication stress tolerance, impairs homologous recombination, and disables checkpoint control, enhancing cytotoxicity from standard therapies including gemcitabine, FOLFIRINOX, fluoropyrimidines, and radiotherapy...Early-phase clinical trials of ATR inhibitors (ART0380, AZD6738, BBI-355) alone or in combination show promising safety, tolerability, and preliminary efficacy. In this review, we summarize current literature on targeting the ATM-CHK2 and ATR-CHK1 pathways in PC, highlighting preclinical evidence, clinical developments, and strategies for biomarker-driven, precision oncology approaches.

Dimensional priming fundamentally reprograms ADSC phenotype and alters their stromal-immune interactions, generating a tumor-permissive state that accelerates PDAC progression. These findings identify mechanical cues as critical regulators of stromal plasticity and highlight dimensional priming as a potentially targetable axis within the PDAC microenvironment.

In the remnant pancreas, completion total pancreatectomy for isolated recurrence of pancreatic ductal adenocarcinoma may offer favorable oncologic outcomes in carefully selected patients-particularly patients with recurrence after 1 year, tumor size <4 cm, and stable tumor marker levels.

A SL just prior to surgical exploration in patients with PDAC following neoadjuvant treatment was able to detect occult metastases with a NNT of 8. Tailored use of SL only in patients with one or two risk factors would further lower this NNT.

P1, N=91, Recruiting, Adlai Nortye Biopharma Co., Ltd. | Not yet recruiting --> Recruiting

P2, N=392, Completed, Zhejiang University | Recruiting --> Completed | Phase classification: P3 --> P2 | N=830 --> 392 | Trial completion date: Dec 2024 --> Nov 2025 | Trial primary completion date: Dec 2023 --> Nov 2025